Halder Venture Board Approves ₹5 Crore Capital Increase and ₹25 Crore Warrant Issuance

2 min read     Updated on 27 Mar 2026, 12:01 AM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Halder Venture Limited's board meeting on March 26, 2026, approved significant corporate actions including a ₹5 crore increase in authorised share capital to ₹18.43 crore and the issuance of 7,93,650 convertible warrants at ₹315 each to P.K. Bio Link Private Limited for ₹24,99,99,750. The board also managed internal auditor transitions, replacing M/s Somnath Ray & Associates with M/s J Kumar Jain & Associates, with all resolutions subject to shareholder approval through postal ballot.

powered bylight_fuzz_icon
35827677

*this image is generated using AI for illustrative purposes only.

Halder Venture Limited has officially concluded its board meeting on March 26, 2026, approving significant corporate actions including capital structure enhancement and fund raising through convertible warrants. The meeting, held at Diamond Heritage, Kolkata, addressed multiple strategic initiatives as outlined in the company's regulatory filing to NSE (Symbol: HALDER) and BSE (Script Code: 539854).

Board Meeting Outcomes

The board of directors approved five key resolutions during the meeting held from 3:00 PM to 4:30 PM at Diamond Heritage, 16 Strand Road, 10th Floor, Unit-1012, Kolkata-700001. The decisions encompass internal auditor changes, capital structure modifications, and fund raising initiatives, all subject to shareholder approval through postal ballot.

Resolution Type: Details
Meeting Duration: 3:00 PM to 4:30 PM
Venue: Diamond Heritage, Kolkata
Total Resolutions: 5 approved
Regulatory Compliance: Regulation 30 of SEBI LODR

Internal Auditor Transition

The board took note of the resignation of M/s Somnath Ray & Associates (FRN: 324411E), Chartered Accountants, as Internal Auditor effective March 18, 2026, due to increased professional commitments and work pressures. Subsequently, the board approved the appointment of M/s J Kumar Jain & Associates (FRN: 330168E), Chartered Accountants, as the new Internal Auditor for Financial Year 2025-2026.

Auditor Details: Outgoing Incoming
Firm Name: M/s Somnath Ray & Associates M/s J Kumar Jain & Associates
FRN: 324411E 330168E
Cessation Date: March 18, 2026 -
Appointment Date: - March 26, 2026
Reason: Pre-occupation New appointment

Authorised Share Capital Enhancement

The board approved a substantial increase in the company's authorised share capital from ₹13.43 crore to ₹18.43 crore, representing an addition of ₹5.00 crore. This enhancement involves creating 50,00,000 additional equity shares of ₹10 each, bringing the total authorised shares to 1,84,25,000 equity shares.

Capital Structure: Current Proposed
Authorised Capital: ₹13.43 crore ₹18.43 crore
Number of Shares: 1,34,25,000 1,84,25,000
Additional Shares: - 50,00,000
Face Value: ₹10 per share ₹10 per share

Convertible Warrants Issuance

The board approved the creation and issuance of 7,93,650 convertible warrants with a face value of ₹10 each at a price of ₹315 per warrant, including a premium of ₹305. The entire warrant allocation will be made to P.K. Bio Link Private Limited, a non-promoter entity, for a total consideration of ₹24,99,99,750.

Warrant Details: Specifications
Total Warrants: 7,93,650
Face Value: ₹10 per warrant
Issue Price: ₹315 per warrant
Premium: ₹305 per warrant
Total Amount: ₹24,99,99,750
Allottee: P.K. Bio Link Private Limited
Category: Non-Promoter
Issuance Type: Preferential allotment

Regulatory Compliance and Implementation

All approved resolutions are subject to shareholder approval through postal ballot, for which the board has also approved the postal ballot notice. The regulatory filing was digitally signed by Ayanti Sen, Company Secretary and Compliance Officer, ensuring compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company operates under CIN No.: L74210WB1982PLC035117 and maintains its headquarters at Diamond Heritage, Kolkata.

Historical Stock Returns for Halder Venture

1 Day5 Days1 Month6 Months1 Year5 Years
-0.53%-2.30%-6.79%-9.24%-9.24%-9.24%

What strategic initiatives will Halder Venture pursue with the ₹25 crore raised through convertible warrants?

How might the significant stake acquisition by P.K. Bio Link Private Limited influence Halder Venture's future business direction and governance?

Will the 37% increase in authorized share capital signal additional fundraising rounds or expansion plans beyond the current warrant issuance?

BSE Rejects Halder Venture's Waiver Application for Rs. 5.42 Lakh Regulatory Fine

1 min read     Updated on 19 Mar 2026, 10:23 AM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

BSE has rejected Halder Venture Limited's waiver application for a Rs. 5.42 lakh fine imposed for non-compliance with board composition regulations during the quarter ended September 2025. The company had submitted the waiver application in December 2025 but received rejection notification in March 2026. The fine relates to violation of Regulation 17(1) pertaining to Board of Directors composition, with no operational impact except the monetary penalty.

powered bylight_fuzz_icon
35441587

*this image is generated using AI for illustrative purposes only.

Halder venture Limited has informed stock exchanges that the Bombay Stock Exchange (BSE) has rejected its waiver application for a regulatory fine imposed due to non-compliance with board composition requirements. The company made this disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

Fine Details and Timeline

The BSE had imposed a fine of Rs. 5.42 lakh including GST through an email dated November 28, 2025, for non-compliance with Regulation 17(1) pertaining to board composition for the quarter ended September 2025. The company had initially disclosed this fine on February 13, 2026, along with board comments on the matter.

Parameter: Details
Fine Amount: Rs. 5.42 lakh (including GST)
Violation: Non-compliance with Regulation 17(1)
Period: Quarter ended September 2025
Fine Notification: November 28, 2025
Waiver Application: December 01, 2025
Rejection Date: March 18, 2026

Waiver Application Process

Halder Venture had submitted a waiver application to BSE on December 01, 2025, explaining its inability to comply with the board composition regulation within the required timeline. However, the company received an email from BSE on March 18, 2026, at 4:41 PM, informing that the waiver application had been rejected.

Regulatory Compliance Details

The fine relates to non-compliance with Regulation 17(1) of SEBI LODR, which pertains to the composition of the Board of Directors. This regulation mandates specific requirements for board composition that listed companies must maintain.

Compliance Aspect: Information
Authority: Bombay Stock Exchange (BSE)
Regulation: 17(1) - Board Composition
Quarter: September 2025
Financial Impact: Rs. 5.42 lakh fine amount
Operational Impact: Nil (except fine amount)

Financial Impact

According to the company's disclosure, there is no impact on financial, operational, or other activities except for the fine amount of Rs. 5.42 lakh including GST imposed by BSE. The company has provided detailed disclosure as required under SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.

The disclosure was signed by Ayanti Sen, Company Secretary and Compliance Officer, and submitted to both NSE and BSE for their records and acknowledgment.

Historical Stock Returns for Halder Venture

1 Day5 Days1 Month6 Months1 Year5 Years
-0.53%-2.30%-6.79%-9.24%-9.24%-9.24%

Will Halder Venture face additional regulatory scrutiny or penalties from SEBI for repeated non-compliance with board composition requirements?

How might this rejected waiver application impact Halder Venture's ability to secure future regulatory relief or exemptions from stock exchanges?

Could this governance issue affect Halder Venture's credit rating or ability to raise capital through equity or debt markets?

More News on Halder Venture

1 Year Returns:-9.24%